Narrative review of the literature on adherence to disease- modifying therapies among patients with multiple sclerosis

Journal of Managed Care Pharmacy

Volumn 19, Issue SUPPL.1, 2013, Pages

  Menzin, Joseph ^a   Caon, Christina ^b   Nichols, Christine ^a   White, Leigh Ann ^c   Friedman, Mark ^a   Pill, Michael W ^d  

^a Boston Health Economics Inc   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BIOGEN   (United States)

^d Gemini Healthcare LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PALIVIZUMAB;

ARTICLE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHYSICAL DISABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84874924558     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.s1.s24     Document Type: Article

References (55)

1. National Multiple Sclerosis Society. Multiple sclerosis: just the facts. July 2011. Available at: www.nationalmssociety.org/download.aspx?id=22. Accessed October 16, 2012.
2. Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78.
3. National Multiple Sclerosis Society. What we know about MS: treatments. 2010. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/ what-we-know-about-ms/treatments/index.aspx. Accessed October 16, 2012.
4. Betaseron (interferon beta-1b) for SC injection. Bayer HealthCare Pharmaceuticals, Inc. May 2010. Available at: http://berlex.bayerhealthcare. com/html/products/pi/Betaseron_PI.pdf. Accessed October 16, 2012.
5. AVONEX (interferon beta-1a) IM injection. Biogen Idec Inc. Revised October 2012. Available at: http://www.avonex.com/pdfs/guides/Avonex_ Prescribing_Information.pdf. Accessed October 16, 2012.
6. Copaxone (glatiramer acetate injection) solution for subcutaneous injection. TEVA Pharmaceuticals, Inc. February 2009. Available at: http://www. sharedsolutions.com/pdfs/PrescribingInformation.aspx. Accessed October 16, 2012.
7. Rebif (interferon beta-1a) SC injection. EMD Serono, Inc. and Pfizer, Inc. September 2011. Available at: http://www.emdserono.com/cmg.emdserono_ us/en/images/rebif_tcm115_19765.pdf. Accessed October 16, 2012.
8. Tysabri (natalizumab) injection for intravenous use. Biogen Idec Inc. January 2012. Available at: http://www.tysabri.com/en_US/tysb/site/pdfs/ TYSABRI-pi.pdf. Accessed October 16, 2012.
9. Extavia (interferon beta-1b) for subcutaneous injection. Novartis Pharmaceuticals Corporation. March 2012. Available at: http://www.pharma. us.novartis.com/product/pi/pdf/extavia.pdf. Accessed October 16, 2012.
10. Ampyra (dalfampridine) extended release tablets, for oral use. Acorda Therapeutics, Inc. Revised August 2012. Available at: http://ampyra.com/ local/files/PI.pdf. Accessed October 16, 2012.
11. Gilenya (fingolimod) capsules. Novartis Pharmaceuticals Corporation. May 2012. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/ gilenya.pdf. Accessed October 16, 2012.
12. Novantrone (mitoxantrone) for injection concentrate. EMD Serono. March 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2012/019297s035lbl.pdf?utm_campaign=Google2&utm_ source=fdaSearch&utm_medium=website&utm_term=novantrone%20 (mitoxantrone&utm_content=8. Accessed October 16, 2012.
13. Brandes DW, Callender T, Lathi E, O'Leary S. A review of diseasemodifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin. 2009;25(1):77-92.
14. Riñon A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629-43.
15. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
16. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.
17. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51-61.
18. Tan H, Yu J, Tabby D, Devries A, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2010;16(8):956-63.
19. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449-63. Available at: http://www.springerlink.com/content/e3170410121767x2/fulltext. pdf. Accessed October 16, 2012.
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
21. Evans C, Tam J, Kingwell E, Oger J, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther. 2012;34(2):341-50.
22. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin. 2010;26(3):663-74.
23. Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc. 2008;48(6):752-57.
24. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Version 5.1.0. March 2011. Available at: http://www.cochrane-handbook.org/. Accessed October 16, 2012.
25. Arroyo E, Grau C, Ramo-Tello C, Parra J, Sanchez-Solino O. Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project. Eur Neurol. 2011;65(2):59-67.
26. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
27. Hancock LM, Bruce JM, Lynch SG. Exacerbation history is associated with medication and appointment adherence in MS. J Behav Med. 2011;34(5):330-35.
28. Zwibel H, Pardo G, Smith S, Denney D, Oleen-Burkey M. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol. 2011;258(3):402-11.
29. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler. 2010;16(1):112-20.
30. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33(3):219-27.
31. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568-76.
32. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6):565-76.
33. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2001;33(5):231-39.
34. Wicks P, Massagli M, Kulkarni A, Dastani H. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J Med Internet Res. 2011;13(1):e12. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3221333/?tool=pubmed. Accessed October 16, 2012.
35. Stockl KM, Shin JS, Gong S, Harada AS, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139-44.
36. Turner AP, Williams RM, Sloan AP, Haselkorn JK. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol. 2009;54(1):116-21.
37. Siegel S, Turner A, Haselkorn J. Adherence to disease-modifying therapies in multiple sclerosis: does caregiver social support matter? Rehabil Psychol. 2008;53(1):73-79.
38. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler. 2007;13(9):1146-52.
39. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. 2004;36(3):120-29.
40. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5:73-84. Available at: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3058604/?tool=pubmed. Accessed October 16, 2012.
41. Dor A, Lage MJ, Tarrants ML, Castelli-Haley J. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. Adv Health Econ Health Serv Res. 2010;22:175-93.
42. Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ. 2010;13(4):633-40.
43. Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting. Clin Neurol Neurosurg. 2010;112(10):876-82.
44. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs. 2003;35(3):163-70.
45. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(6 Suppl):S136-S143.
46. Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011;38(3):429-33.
47. Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data. J Neurosci Nurs. 2010;42(5 Suppl):S5-S9.
48. Edlin M, Sonnenreich P. Trends in managing multiple sclerosis. P T. 2008;33(10):611-14. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2730792/?tool=pubmed. Accessed October 16, 2012.
49. Jacobson VJ, Feaganes J, Wegner S. Reliability of Medicaid claims versus medical record data: in a cost analysis of palivizumab. Pharmacoeconomics. 2007;25(9):793-800.
50. Ivanova JI, Bergman RE, Birnbaum HG, Phillips, AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601-09.
51. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology. 2010;74(Suppl 3):S24-S35.
52. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15(2):259-71.
53. Aforismo J, Pill M, Prescott J. Initiating drug therapy in multiple sclerosis patients: effects on healthcare costs. Am J Pharm Benefits. 2010;2(1):59-65.
54. Brandes DW, Shaya FT, Pill MW. Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis. Am J Manag Care. 2010;16(6 Suppl):S171-S177.
55. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52.